Influence of the severity and treatment of allergic rhinitis and asthma on SARS-CoV-2 infection.
10.3760/cma.j.cn112150-20230131-00067
- Author:
Li Sha LI
1
;
Kai GUAN
1
Author Information
1. Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Humans;
COVID-19;
SARS-CoV-2/metabolism*;
Peptidyl-Dipeptidase A/metabolism*;
Asthma/therapy*;
Rhinitis, Allergic
- From:
Chinese Journal of Preventive Medicine
2023;57(8):1171-1175
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected 660 million people and resulted in 6.7 million deaths. At present, a variety of risk factors related to the severity of COVID-19 have been identified, but whether allergic rhinitis and asthma will affect SARS-CoV-2 infection remains controversial. In general, there is no sufficient evidence to support that allergic rhinitis or asthma is a risk factor for increasing the rate of SARS-CoV-2 infection or aggravating the disease. Some studies even show that atopy may be a protective factor to alleviate SARS-CoV-2 infection, which is related to the decreased expression of angiotensin-converting enzyme 2, the receptor required for SARS-CoV-2 to enter cells, in atopic individuals. This paper reviews the influence of the severity and treatment of allergic rhinitis and asthma on SARS-CoV-2 infection, in order to provide some references for establishing strategies for prevention, risk stratification and treatment of COVID-19.
